228 related articles for article (PubMed ID: 32036069)
1. Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma.
Zhao S; Fang W; Pan H; Yang Y; Liang Y; Yang L; Dong X; Zhan J; Wang K; Zhang L
J Thorac Oncol; 2020 Jun; 15(6):962-972. PubMed ID: 32036069
[TBL] [Abstract][Full Text] [Related]
2. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
Koga T; Kobayashi Y; Tomizawa K; Suda K; Kosaka T; Sesumi Y; Fujino T; Nishino M; Ohara S; Chiba M; Shimoji M; Takemoto T; Suzuki M; Jänne PA; Mitsudomi T
Lung Cancer; 2018 Dec; 126():72-79. PubMed ID: 30527195
[TBL] [Abstract][Full Text] [Related]
3. First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.
Han H; Zhang X; Liu X; Zhao J; Zhang J; Zhang J; Zhu H; Jiao S; Tang H
Medicine (Baltimore); 2023 Dec; 102(52):e36667. PubMed ID: 38206746
[TBL] [Abstract][Full Text] [Related]
4. Targeting
Han H; Li S; Chen T; Fitzgerald M; Liu S; Peng C; Tang KH; Cao S; Chouitar J; Wu J; Peng D; Deng J; Gao Z; Baker TE; Li F; Zhang H; Pan Y; Ding H; Hu H; Pyon V; Thakurdin C; Papadopoulos E; Tang S; Gonzalvez F; Chen H; Rivera VM; Brake R; Vincent S; Wong KK
Cancer Res; 2021 Oct; 81(20):5311-5324. PubMed ID: 34380634
[TBL] [Abstract][Full Text] [Related]
5. Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.
Kosaka T; Tanizaki J; Paranal RM; Endoh H; Lydon C; Capelletti M; Repellin CE; Choi J; Ogino A; Calles A; Ercan D; Redig AJ; Bahcall M; Oxnard GR; Eck MJ; Jänne PA
Cancer Res; 2017 May; 77(10):2712-2721. PubMed ID: 28363995
[TBL] [Abstract][Full Text] [Related]
6. Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma.
Fang W; Zhao S; Liang Y; Yang Y; Yang L; Dong X; Zhang L; Tang Y; Wang S; Yang Y; Ma X; Wang M; Wang W; Zhao S; Wang K; Gao S; Zhang L
Oncologist; 2020 Mar; 25(3):e545-e554. PubMed ID: 32162827
[TBL] [Abstract][Full Text] [Related]
7. A systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer.
Shen X; Chen B; Ma Z; Xie B; Cao X; Yang T; Zhao Y; Qin J; Li J; Cao F; Chen X
J Recept Signal Transduct Res; 2016; 36(1):89-97. PubMed ID: 26391018
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor.
Jang J; Son J; Park E; Kosaka T; Saxon JA; De Clercq DJH; Choi HG; Tanizaki J; Eck MJ; Jänne PA; Gray NS
Angew Chem Int Ed Engl; 2018 Sep; 57(36):11629-11633. PubMed ID: 29978938
[TBL] [Abstract][Full Text] [Related]
9. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
Chen K; Pan G; Cheng G; Zhang F; Xu Y; Huang Z; Fan Y
Thorac Cancer; 2021 Jan; 12(2):218-226. PubMed ID: 33210451
[TBL] [Abstract][Full Text] [Related]
10. EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins.
Remon J; Hendriks LEL; Cardona AF; Besse B
Cancer Treat Rev; 2020 Nov; 90():102105. PubMed ID: 32979839
[TBL] [Abstract][Full Text] [Related]
11. Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.
Lai WV; Lebas L; Barnes TA; Milia J; Ni A; Gautschi O; Peters S; Ferrara R; Plodkowski AJ; Kavanagh J; Sabari JK; Clarke SJ; Pavlakis N; Drilon A; Rudin CM; Arcila ME; Leighl NB; Shepherd FA; Kris MG; Mazières J; Li BT
Eur J Cancer; 2019 Mar; 109():28-35. PubMed ID: 30685684
[TBL] [Abstract][Full Text] [Related]
12. Real-World Clinical Outcomes for Patients with
Li K; Bosdet I; Yip S; Ho C; Laskin J; Melosky B; Wang Y; Sun S
Curr Oncol; 2023 Jul; 30(8):7099-7111. PubMed ID: 37622996
[TBL] [Abstract][Full Text] [Related]
13. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.
Kobayashi Y; Togashi Y; Yatabe Y; Mizuuchi H; Jangchul P; Kondo C; Shimoji M; Sato K; Suda K; Tomizawa K; Takemoto T; Hida T; Nishio K; Mitsudomi T
Clin Cancer Res; 2015 Dec; 21(23):5305-13. PubMed ID: 26206867
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Genomic Features of
Tan AC; Saw SPL; Chen J; Lai GGY; Oo HN; Takano A; Lau DPX; Yeong JPS; Tan GS; Lim KH; Skanderup AJ; Chan JWK; Teh YL; Rajasekaran T; Jain A; Tan WL; Ng QS; Kanesvaran R; Lim WT; Ang MK; Tan DSW
JCO Precis Oncol; 2022 Oct; 6():e2200278. PubMed ID: 36240473
[TBL] [Abstract][Full Text] [Related]
15. Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy.
Tian P; Zeng H; Ji L; Ding Z; Ren L; Gao W; Fan Z; Li L; Le X; Li P; Zhang M; Xia X; Zhang J; Li Y; Li W
Lung Cancer; 2021 Oct; 160():50-58. PubMed ID: 34403912
[TBL] [Abstract][Full Text] [Related]
16. Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib.
Yamaoka T; Ohba M; Matsunaga Y; Tsurutani J; Ohmori T
J Vis Exp; 2019 Jun; (148):. PubMed ID: 31305510
[TBL] [Abstract][Full Text] [Related]
17. Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study.
Yang B; Zhang H; Wang H
J Mol Model; 2015 Feb; 21(2):24. PubMed ID: 25620423
[TBL] [Abstract][Full Text] [Related]
18. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Robichaux JP; Elamin YY; Vijayan RSK; Nilsson MB; Hu L; He J; Zhang F; Pisegna M; Poteete A; Sun H; Li S; Chen T; Han H; Negrao MV; Ahnert JR; Diao L; Wang J; Le X; Meric-Bernstam F; Routbort M; Roeck B; Yang Z; Raymond VM; Lanman RB; Frampton GM; Miller VA; Schrock AB; Albacker LA; Wong KK; Cross JB; Heymach JV
Cancer Cell; 2019 Oct; 36(4):444-457.e7. PubMed ID: 31588020
[TBL] [Abstract][Full Text] [Related]
19. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
[TBL] [Abstract][Full Text] [Related]
20. Specific
Yang G; Xu H; Hu J; Liu R; Hu P; Yang Y; Li W; Hao X; Zhang S; Xu F; Ai X; Li J; Wang Y
Front Pharmacol; 2022; 13():806737. PubMed ID: 35330827
[No Abstract] [Full Text] [Related]
[Next] [New Search]
